share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Harris Matthew Scott

SEC announcement ·  Feb 1 18:02
Summary by Moomoo AI
Matthew Scott Harris, Chief Medical Officer of Altimmune, Inc., completed a series of transactions involving the company's common stock over the course of January 30 and 31, 2024. On January 30, Harris exercised options to acquire 9,275 shares at no cost and subsequently disposed of 2,709 shares at a price of $9.80 per share to cover exercise prices or tax liabilities, resulting in a total market value of $26,548.20 for the disposed shares. The following day, Harris acquired an additional 3,257 shares at $2.69 per share through a grant or award. After these transactions, Harris's direct holdings in Altimmune common stock increased to a total of 43,825 shares.
Matthew Scott Harris, Chief Medical Officer of Altimmune, Inc., completed a series of transactions involving the company's common stock over the course of January 30 and 31, 2024. On January 30, Harris exercised options to acquire 9,275 shares at no cost and subsequently disposed of 2,709 shares at a price of $9.80 per share to cover exercise prices or tax liabilities, resulting in a total market value of $26,548.20 for the disposed shares. The following day, Harris acquired an additional 3,257 shares at $2.69 per share through a grant or award. After these transactions, Harris's direct holdings in Altimmune common stock increased to a total of 43,825 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more